The High Cost of Drug Price Controls
Commentary By
The debate over expanding government control of our health sector should have ended during the COVID-19 pandemic:
Where there have been failures in responding to the crisis, it has been a failure of big government such as the Centers for Disease Control and Prevention’s arrogant and clumsy insistence on controlling early development of testing that delayed the U.S. response and surely cost lives. Or the failure to protect those most at risk, especially seniors in nursing homes. Or CDC’s decades-long refusal to develop a modern data tracking system.
House Energy and Commerce to Hold Hearing on Drug Pricing Legislation
Senate
Senators Thune and Carper Reintroduce Bill on Chronic Disease Management
Administration
Biden Administration to Divert Raw Materials for COVID-19 Vaccine and Provide Other Supplies to India
CDC Issues New Guidance for Vaccinated Americans
FDA Panel Votes to Keep Tecentriq on the Market
FDA to Propose Menthol Ban in Next Year
HHS Will Distribute $1 Billion for Community Health Centers
HHS Removes Some Prescribing Barriers for Buprenorphine
Final Rules
CMS Extends Comprehensive Joint Replacement Model Demonstration for Three Years
Proposed Rules
CMS Issues Proposed Rule on Payment Rates and Policies for Inpatient and Long-Term Hospitals
To embed, copy and paste the code into your website or blog:
The U.S. House of Representatives is considering dueling proposals related to drug pricing under Medicaid and Medicare, including the Republican-led H.R. 19, the “Lower Costs, More Cures Act of 2021” and a reintroduced version of the Democrat-led “Elijah E. Cummings Lower Drug Costs Now Act,” originally introduced in 2019 (and hereinafter referred to) as H.R. 3. Although the bills diverge in various material respects, both would implement sweeping changes related to drug coverage and price reporting. At the same time that the House considers these proposals, Senate Democrats are urging President Biden to include major drug pricing legislation in the second phase of his infrastructure plan. The White House has been silent to date on whether drug pricing will be addressed in the next proposed infrastructure package.
Hearing on Negotiating a Better Deal: Legislation to Lower the Cost of Prescription Drugs house.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from house.gov Daily Mail and Mail on Sunday newspapers.
Examining Our COVID-19 Response: Using Lessons Learned to Address Mental Health and Substance Use Disorders”
10:00 a.m.
Senate Appropriations Committee Subcommittee on the Interior, Environment, and Related Agencies Hearing:
“Addressing Health Disparities in Indian Country: Review of the Indian Health Service’s COVID Response and Future Needs”
10:00 a.m.
Senate Appropriations Committee Subcommittee on Military Construction, Veterans Affairs, and Related Agencies Hearing:
“VA Telehealth Program: Leveraging Recent Investments to Build Future Capacity”
3:00 p.m.
May 4
House Energy and Commerce Committee Hearing: “
To Discuss the Reintroduction of the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3)”
House
House Republicans Introduce Drug Pricing Legislation